NewsLSE Cannabis Debutant Company MGC Pharma Set ‘To Break...

LSE Cannabis Debutant Company MGC Pharma Set ‘To Break Even This Year’


THE London Stock Exchange’s medical cannabis debutant MGC Pharmaceuticals has released is first quarterly update since listing showing record revenues of almost £500,000.

In the market update for the quarter up to March 31, it announced it has signed a supply deal to provide nutraceuticals producer and distributor Swiss PharmaCan a minimum of 40,000 units, per quarter, of its Covid-19 alleviating drug ArtemiC.

It reported progress on a number of trial initiatives including the launch of an in-vitro study into the treatment of aggressive glioblastoma brain cancer.

Roby Zomer, CEO of MGC Pharma, said: “This has been an historic quarter for MGC Pharma, following our listing on LSE, along with record sales for our proprietary pharmaceutical products. 

“MGC Pharma is well positioned for the future, with clinical trials for CannEpil and CogniCann due to begin in the coming quarter, alongside phase III clinical trials for CimetrA, which have the potential to treat the many people suffering as a result of Covid-19.

“MGC Pharma is now in an excellent position to realise its potential and build on the foundations that have been set in the past 12 months, as we remain on target to reach break even this financial year.”

MGC Pharma is dual-listed on both the Australian Securities Exchange and the LSE and valued at around £80m.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

Latest news

European Cannabis Stocks Review: Celadon Shares Spike 150% On Licence Update, OCT Continues Recovery, & Creso Pharma Censured By ASX

Celadon Pharmaceuticals  Celadon Pharmaceuticals stock has skyrocketed by more than 150% this week following the announcement that its current Home...

Benefits of F1 Cannabis Hybrids from Royal Queen Seeds

F1 hybrids have revolutionised the way we grow and use plants. Now, F1 cannabis seeds are bringing growers, smokers,...

Celadon Pharmaceuticals Announces Home Office Approval Of Licence For Commercial Sale Of GMP Cannabis

PRESS RELEASE FURTHER to the announcement dated 16 January 2023, Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on...

Proposed Changes To Germany’s Medical Cannabis Framework Would ‘Seriously Impact Both Patients And Industry’ If Brought In Tomorrow

TOMORROW, Germany’s Federal Joint Committee (G-BA) is expected to announce major changes to the country’s medical cannabis framework.  These could...

Will Twitter’s ‘Relaxation’ On Cannabis Advertising Help Break The Industry’s Social Media Ad Embargo?

TWITTER has become the first major social media platform to openly allow the advertisement of cannabis brands.  Since the new...

Kanabo Launches New Online Medical Cannabis Clinic ‘Treat It’, Offering Access To Doctors In ‘Less Than 24 Hours’

KANABO Group has today announced the launch of a new online medical cannabis clinic for pain management, Treat It.  The...

Must read

You might also likeRELATED
Recommended to you